“Multi-Spectral Imaging has the ability to detect changes at the layers of the RPE before anything that we know of now. We can’t see these changes with photographs, we can’t even see it with autofluorescence. But we can see it with the RHA at selected layers. So, we have the ability to find patients who have the earliest changes. That’s very significant. In addition, MSI will enable imaging of the vitreoretinal interface and help clinicians assess the effects of drugs such as Jetrea (ocriplasmin, ThromboGenics) on vitreomacular traction.”
You are here
“This technology promises to not only revolutionize clinical practice, but also greatly enhance our understanding of the pathophysiology of retinal and choroidal disease."
" Annidis Multi-Spectral Imaging provides incredible images of the RPE and choroid without the need for special dye. This is extremely useful for the diagnosis of polypoidal choroidal vasculopathy (PCV). This is not only cost effective, it is also less invasive for the patient. The opportunity to image oxyhemoglobin and deoxyhemoglobin will open a new way to study retinal diseases such as DME and RVO."
"Multi-Spectral Imaging technology allows ophthalmologists to see through the layers of the retina en face. It maps the posterior pole so that ophthalmologists can obtain a global picture of pathology rather than cross sections. This global view will help refine our clinical decisions and enhance our identification of pathology. It will provide prognostic biomarkers for disease progression and therapeutic response for conditions such as macular degeneration and diabetic retinopathy."
Michael Tolentino MD is Associate Professor Ophthalmology at University of Central Florida and Director of Research at Center for Retina and Macular Disease.
“The Annidis technology solution is a major advancement in retinal health management and a potentially significant tool for assisting eye care professionals in the diagnosis and monitoring of sight-threatening eye diseases.”